⌘K
Loading ticker…
As of 2026-08-21, Neumora Therapeutics, Inc. Common Stock (NMRA) has a 3-month relative strength percentile of 27 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 41. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.0%, relative volume 0.65×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
NMRA is held by 7 ETFs as of May 2026. Top owner: SCHA at 0.00% weight, $769K notional. Top 3 carry $1M.
Held by 15 ETFs · $11M across latest filings · largest weight 0.15% (IBRN).
Top 7 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.00% | $769K | — |
| VHTVanguard Health Care ETF | 0.00% | $333K | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $94K | — |
| AVSC | 0.00% | $47K | — |
| IBBQ | 0.02% | $16K | −0.02 pp |
| BIB | 0.02% | $11K | −0.01 pp |
| AVTM | 0.00% | $2K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NMRA Jan avg: -27.74% median: -12.61% win: 33% σ: 48.30% n: 3 2023-09-18 → 2026-07-31 | NMRA Feb avg: 24.84% median: 18.32% win: 67% σ: 47.61% n: 3 2023-09-18 → 2026-07-31 | NMRA Mar avg: -34.01% median: -35.90% win: 0% σ: 11.18% n: 3 2023-09-18 → 2026-07-31 | NMRA Apr avg: -9.75% median: -22.02% win: 33% σ: 32.09% n: 3 2023-09-18 → 2026-07-31 | NMRA May avg: -8.11% median: -8.14% win: 33% σ: 17.01% n: 3 2023-09-18 → 2026-07-31 | NMRA Jun avg: -2.15% median: -0.71% win: 33% σ: 5.39% n: 3 2023-09-18 → 2026-07-31 | NMRA Jul avg: 64.27% median: 30.82% win: 67% σ: 91.02% n: 3 2023-09-18 → 2026-07-31 | NMRA Aug avg: -11.15% median: -11.15% win: 0% σ: 0.82% n: 2 2023-09-18 → 2026-07-31 (current) | NMRA Sep avg: 2.30% median: 5.20% win: 67% σ: 14.24% n: 3 2023-09-18 → 2026-07-31 | NMRA Oct avg: 10.00% median: -13.32% win: 33% σ: 48.66% n: 3 2023-09-18 → 2026-07-31 | NMRA Nov avg: -8.95% median: -13.19% win: 33% σ: 19.36% n: 3 2023-09-18 → 2026-07-31 | NMRA Dec avg: 8.58% median: 6.64% win: 67% σ: 29.68% n: 3 2023-09-18 → 2026-07-31 |